Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CACA 2025 | Gastroenteropancreatic neuroendocrine tumors and liver metastases in China

Chunhui Yuan • 6 Nov 2025
CACA 2025
Neuroendocrine Tumor

Chunhui Yuan, MD, Peking University Third Hospital, Beijing, China, discusses the epidemiology and current treatment strategies for gastroenteropancreatic neuroendocrine tumors (GI-NETs). Whilst GI-NETs are more prevalent in the west, pancreatic neuroendocrine tumors are more common in China, which can be attributed to differences in screening and diagnostic procedures. This interview took place at the 2025 Chinese Anti-Cancer Association (CACA) Science & Technology Award Talks in Kunming, China.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

Prognostic biomarkers and predictors of outcome in patients with neuroendocrine tumors
1:40
Prognostic biomarkers and predictors of outcome in patients with neuroendocrine tumors
Rocio Garcia-Carbonero • 2 Jul 2026
DLL3: a promising target in neuroendocrine carcinomas
2:44
DLL3: a promising target in neuroendocrine carcinomas
Rocio Garcia-Carbonero • 2 Jul 2026
Current and emerging strategies for targeting NETs
7:13
Current and emerging strategies for targeting NETs
Rocio Garcia-Carbonero • 2 Jul 2026
Phase I trial of LB2102 CAR-T therapy in R/R SCLC and LCNEC
1:43
Phase I trial of LB2102 CAR-T therapy in R/R SCLC and LCNEC
Zhonglin Hao • 31 May 2026
The content of VJOncology is intended for healthcare professionals